MediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime Inhaler

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specializing in precision-based cannabinoids, is pleased to announce it has launched the new Shake & Puff CBN THC Nighttime Inhaler in Canada. This innovative product expands MediPharm’s leading CBN oil product portfolio and builds on the success of the Company’s THC Inhaler introduced earlier this year.

The new metered dose inhaler delivers a precise formulation of minor cannabinoid CBN and THC in a consistent, smoke-free format. Designed for nighttime use, the product offers a fast onset experience without combustion or vapour, making it a discreet and convenient option for both consumers and medical patients.

David Pidduck, CEO of MediPharm Labs, commented:

"The launch of our CBN THC Metered Dose Inhaler represents a significant step forward in our strategy to deliver innovative, pharma-grade cannabinoid products globally. As international markets increasingly seek smoke-free, precisely dosed formats, MediPharm is well-positioned to lead with differentiated solutions that reflect both consumer wellness trends and medical needs. This product not only strengthens our Canadian portfolio but also supports our broader vision to scale precision cannabinoid delivery methods across regulated cannabis markets worldwide."

Key Product Highlights:

• Metered dose inhaler format ensures precision and repeatability for consistent outcomes.
• Smoke-free and vapour-free delivery with rapid onset.
• Familiar format similar to asthma inhalers, offering comfort and ease of use.
• Discreet and portable, with no lingering smell or by-products.
• Direct to lung delivery for higher bioavailability of CBN and THC compared to ingested formats.
• Available now through select Ontario adult-use retailers and nationally via the Canna Farms medical platform, with expansion to additional provinces and channels planned.
  
  
  
  

The Company plans to expand their inhaler offering with additional CBD and CBG options available in the future. MediPharm Labs continues to lead in pharma-grade cannabinoid innovation, offering a diverse range of product formats tailored to the evolving needs of consumers and patients. Inhaled formats like the metered dose inhaler provide rapid onset, while other MediPharm Labs products, such as tinctures, soft chews, and soft gels offer a slower onset and longer-lasting effects.

About MediPharm Labs

MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API), and advanced derivative products utilizing a Good Manufacturing Practices (GMP) certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies, and purpose-built facilities for the delivery of pure, trusted, and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages, and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.

In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company’s current foreign drug manufacturing site registration with the US FDA.

In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm’s reach to medical patients in Canada via Canna Farms medical e-commerce platform, and in Australia and Germany through Beacon Medical PTY and Beacon Medical GMBH. This acquisition also included Harvest Medical Clinics in Canada, which provides medical cannabis patients with physician consultations for medical cannabis education and prescriptions.

The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.

For further information, please contact:

MediPharm Labs Investor Relations

Telephone: +1 416.913.7425

Email: 

Website: 

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events, or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events, or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, MediPharm’s access to and unique position in the international medical markets, MediPharm’s future growth and ability to scale precision cannabinoid delivery methods across regulated cannabis markets worldwide, MediPharm’s timing and ability to distribute its metered dose inhalers in Canada, MediPharm’s ability to further expand its international portfolio, future growth of cannabinoid products in international markets, wellness trends and medical needs of consumers, and the success of MediPharm’s products in Canada, including MediPharm’s ability to expand distribution of its metered dose inhaler products to additional provinces and channels. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political, and social uncertainties; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR+ website at . There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

A photo accompanying this announcement is available at